Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Kontron Aktie 10395864 / AT0000A0E9W5

05.11.2025 07:00:03

EQS-News: Kontron Achieves Strong Margin Growth

EQS-News: Kontron AG / Key word(s): Quarter Results
Kontron Achieves Strong Margin Growth

05.11.2025 / 07:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


  • 9-Month Figures: EBITDA climbs to EUR 194 million (PY: 141 million), consolidated net income (after minority interests) to EUR 111 million (PY: EUR 62 million)
  • Operating EBITDA margin rises to 12.5% (PY: 11.7%)
  • 9-Month operating cash flow of EUR 49.7 million (PY: EUR 2.8 million)
  • Order intake of EUR 1,548 million with revenue of EUR 1,182 million, resulting in a book-to-bill ratio of 1.31
  • Earnings forecast for 2025 confirmed

Linz, 05.11.2025: Kontron, a leading global provider of IoT technology, today announced its results for the first nine months of the 2025 financial year, thereby confirming the preliminary figures published on October 29, 2025.

Kontron increased sales to EUR 1,181.9 million in the first nine months of the 2025 financial year (PY: EUR 1,207.7 million). The moderate decline is due to the divestment of the COM business. EBITDA reached EUR 193.6 million in the 9-month period of 2025, up 37% on the previous year's figure of EUR 141.4 million, including a one-off effect of around EUR 46 million. Consolidated net income after minority interests rose to EUR 110.8 million (PY: EUR 62.3 million) or EUR 1.80 per share (PY: EUR 1.01) after nine months in the 2025 financial year.

Equity increased to EUR 714.8 million as of September 30, 2025 (December 31, 2024: EUR 652.3 million), and the equity ratio improved to 40.6% (December 31, 2024: 35.8%) compared to the 2024 balance sheet date. Operating cash flow in the 9-month period of 2025 amounted to EUR 49.7 million (PY: EUR 2.8 million). Kontron benefited from continued strong demand and was able to increase its high order backlog once again. The order backlog as of September 30, 2025 was EUR 2,444 million (December 31, 2024: EUR 2,078 million). The project pipeline increased to EUR 7,802 million at the end of September 2025 (December 31, 2024: EUR 6,643 million), underpinning Kontron's growth potential beyond the 2025 financial year. The book-to-bill ratio for the first nine months of 2025 was 1.31 (PY: 1.19).

In addition to the overall strong operating performance, the consistent execution of the high-margin product strategy is one of the highlights in 2025. Despite the divestment of around EUR 250 million in revenue per year from low-margin IT, EMS and COM business, profits increased significantly. As part of this strategy, Kontron has systematically streamlined its portfolio in order to clearly focus on its core business in the Internet of Things ("IoT") and to position itself as the leading global technology provider. As a result, the gross margin has increased from 34.7% in 2022 to 41.7% in 2025 and even 43.4% in Q3 2025 over the past three years, based on strong growth in the high-margin Software and Solutions segment.

The momentum in order intake remains strong. Demand is particularly high in the railway infrastructure, defense and aerospace sectors. In the high-speed rail sector, Kontron has already recorded more than EUR 300 million in new orders in 2025, with its strong technological position in the future FRMCS rail standard proving to be a decisive success factor. In the defense sector, demand for data communication and encryption technologies in particular has risen sharply. With its Kontron-OS operating system, specifically designed for cybersecurity, Kontron became the first provider to introduce CRA (Cyber Resilience Act) compliant IoT solutions with AI support.

"Against the backdrop of the successful business development in the first nine months of 2025, the high order backlog, and robust demand, Kontron is confident about the rest of the year and beyond the 2025 financial year," says Hannes Niederhauser, CEO of Kontron. 

As communicated in the publication of the preliminary figures on October 29, 2025, revenue for the full year 2025 is expected to be EUR 1.7 billion, reflecting the discontinuation of the COM, EMS and IT businesses and the focus on higher-margin business. Kontron expects EBITDA to remain unchanged at approximately EUR 270 million. This includes around EUR 220 million in operating EBITDA as well as non-recurring income from portfolio streamlining.

The 9-month report is available at www.kontron.com.

 

About Kontron

Kontron AG (www.kontron.com, ISIN AT0000A0E9W5, WKN A0X9EJ, KTN) is a leading IoT technology company. For more than 20 years, Kontron has been supporting companies from a wide range of industries to achieve their business goals with intelligent solutions. From automated industrial operations, smarter and safer transport to advanced communications, connectivity, medical, and energy solutions, the company delivers technologies that add value for its customers. Kontron has around 7,000 employees in over 20 countries worldwide and is listed on the SDAX® and TecDAX® of the German Stock Exchange.

 

Follow Kontron:

 

Media Contacts

Alexandra Kentros
Kontron AG - Communications
Tel: +49 (0) 151 151 938 81
group-pr@kontron.com
Leon-Philipp Kleiss
Kontron AG – Investor Relations
Tel: +43 (0) 664 60191 5153
ir@kontron.com
 
 
 
 
 
 

All rights reserved. Kontron is a trademark or registered trademark of Kontron Europe GmbH. All other brand or product names are trademarks or registered trademarks or copyrights by their respective owners and are recognized. All data is for information purposes only and not guaranteed for legal purposes. Subject to change without notice. Information in this press release has been carefully checked and is believed to be accurate; however, no responsibility is assumed for inaccuracies.

 



05.11.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


Language: English
Company: Kontron AG
Industriezeile 35
4020 Linz
Austria
Phone: +43 (732) 7664 - 0
E-mail: ir@kontron.com
Internet: https://www.kontron.com
ISIN: AT0000A0E9W5
WKN: A0X9EJ
Indices: SDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange; BX, Vienna Stock Exchange (Vienna MTF)
EQS News ID: 2223874

 
End of News EQS News Service

2223874  05.11.2025 CET/CEST

Analysen zu Kontron

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
06.11.25 Kontron Buy Warburg Research
05.11.25 Kontron Buy Jefferies & Company Inc.
30.10.25 Kontron Buy Warburg Research
30.10.25 Kontron Buy Jefferies & Company Inc.
06.08.25 Kontron Buy Warburg Research
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Mittwoch um 18 Uhr live: Die Illusion der Erinnerung - Wie du Denkfehler im Trading vermeidest

Erfahrung ist wertvoll - doch Erinnerungen sind trügerisch. Sie verzerren, ergänzen oder lassen Details weg, bis ein falsches Bild entsteht. Dieses Webinar zeigt, warum das Gehirn keine objektive Aufzeichnung liefert und wie diese Verzerrungen Trading-Entscheidungen unbewusst beeinflussen.

Schnell noch Plätze sichern!

Abnehmspritzen – Ist der Hype vorbei? – mit Tim Schäfer

Ist der Hype um Abnehmspritzen wie bei Novo Nordisk und Eli Lilly vorbei – oder stehen wir erst am Anfang einer langfristigen Revolution im Gesundheitswesen? 💉📉

Im heutigen Gespräch mit Tim Schäfer @TimSchaeferMedia sprechen wir über die spannendsten Pharmawerte 2025. Neben den Abnehmspritzen blicken wir auch auf klassische Pharma-Giganten wie Pfizer, Johnson & Johnson, Roche, Novartis, AstraZeneca und GSK. Tim analysiert Übertreibungen, Rücksetzer und langfristige Chancen für Buy-and-Hold-Strategien – mit Fokus auf Dividende, KGV und Krisenresistenz.

💬 Was ist vom Abnehmtrend langfristig zu halten?
💬 Welche Pharma-Aktien sind aktuell unterbewertet?
💬 Was spricht für konservative Dividendenwerte im Gesundheitssektor?

👉🏽 https://bxplus.ch/wall-street-live-mit-tim-schaefer/

Abnehmspritzen – Ist der Hype vorbei? – Wall Street Live mit Tim Schäfer

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’974.31 19.37 BP9SUU
Short 13’215.46 13.98 BU9S6U
Short 13’724.19 8.85 B19SNU
SMI-Kurs: 12’546.01 11.11.2025 09:12:32
Long 11’962.62 19.84 SNLBQU
Long 11’690.01 13.82 SSTBSU
Long 11’209.46 8.98 SQZB6U
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

Aktien in diesem Artikel

Kontron 21.07 -0.13% Kontron